Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on January 4, 2018. The filing reports the entry into a material definitive agreement regarding the company's debt financing structure.
Key Financial Metrics
The filing details a revision to the company's Loan and Security Agreement with Hercules Capital, Inc. Key debt metrics include:
- Total Borrowing Capacity: Increased from $25.0 million to $50.0 million.
- Outstanding Borrowings: $15.0 million (borrowed prior to this amendment).
- Remaining Borrowing Capacity: $35.0 million.
- Tranche Structure: The remaining capacity consists of up to $10.0 million in "Term E Loan Advances" and up to $25.0 million in "Term F Loan Advances."
The filing does not provide specific data on revenue, profit, cash flow, margins, or liquidity ratios.
Material Changes
The primary material change is the doubling of the company's credit facility limit. The First Amendment to the Loan and Security Agreement, dated January 4, 2018, supersedes the original agreement dated March 21, 2017, raising the maximum principal amount available to the company.
Conditions, Risks, and Outlook
Access to the additional $35.0 million in borrowing capacity is subject to specific conditions and discretion:
- Term E Loan Advances: Drawing these funds requires the U.S. Food and Drug Administration (FDA) to accept the company's new drug application for duvelisib on or before September 30, 2018. Additionally, the company must deliver financial and business projections acceptable to Hercules.
- Term F Loan Advances: These are subject to the prior drawing of all other tranches and are at the sole discretion of Hercules.
- Terms: If drawn, additional tranches will bear interest and have the same maturity as existing loans under the agreement.
Investor Verification Checklist
- Verify the status of the FDA new drug application for duvelisib to assess the likelihood of accessing the $10.0 million Term E tranche.
- Review the full text of the First Amendment (Exhibit 10.1) for specific interest rates, maturity dates, and covenants not detailed in this summary.
- Confirm the company's current cash position and burn rate to evaluate the necessity of drawing the remaining $35.0 million.
- Check subsequent filings for any updates on the acceptance of the duvelisib application or the drawing of additional loan tranches.